Amgen VP of R&D David Reese
Amgen rolls out data for KRAS inhibitor combo study in colorectal cancer, hoping to move on from ugly early results
With the first win for its KRAS inhibitor sotorasib in hand, Amgen is pushing ahead with an aggressive clinical plan to capitalize on its first …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.